Page 131 - Read Online

Luo et al. Microbiome Res Rep 2025;4:10 https://dx.doi.org/10.20517/mrr.2024.57 Page 21 of 25

70. Platteeuw C, van Alen-Boerrigter I, van Schalkwijk S, de Vos WM. Food-grade cloning and expression system for Lactococcus
lactis. Appl Environ Microbiol 1996;62:1008-13. DOI PubMed PMC
71. Kim JH, Mills DA. Improvement of a nisin-inducible expression vector for use in lactic acid bacteria. Plasmid 2007;58:275-83. DOI
PubMed
72. Chae JP, Pajarillo EA, Hwang IC, Kang DK. Construction of a Bile-responsive expression system in Lactobacillus plantarum. Food
Sci Anim Resour 2019;39:13-22. DOI PubMed PMC
73. Guan C, Yuan Y, Ma Y, et al. Development of a novel expression system in lactic acid bacteria controlled by a broad-host-range
promoter P srfA . Microb Cell Fact 2022;21:23. DOI PubMed PMC
74. Isabella VM, Ha BN, Castillo MJ, et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease
phenylketonuria. Nat Biotechnol 2018;36:857-64. DOI
75. Jiang Y, Sun B, Qian F, et al. Expression of phenylalanine ammonia lyase as an intracellularly free and extracellularly cell surface-
immobilized enzyme on a gut microbe as a live biotherapeutic for phenylketonuria. Sci China Life Sci 2023;66:127-36. DOI
PubMed PMC
76. Puurunen MK, Vockley J, Searle SL, et al. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of
phenylketonuria: a first-in-human phase 1/2a study. Nat Metab 2021;3:1125-32. DOI
77. Adolfsen KJ, Callihan I, Monahan CE, et al. Improvement of a synthetic live bacterial therapeutic for phenylketonuria with
biosensor-enabled enzyme engineering. Nat Commun 2021;12:6215. DOI PubMed PMC
78. Triassi AJ, Fields BD, Monahan CE, et al. Redesign of an Escherichia coli Nissle treatment for phenylketonuria using insulated
genomic landing pads and genetic circuits to reduce burden. Cell Syst 2023;14:512-24.e12. DOI
79. Heineman HS, Jensen WN, Cooper WM, Braude AI. Hodgkin’s disease and salmonella typhimurium infection. JAMA 1964;188:632-
4. PubMed
80. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene
induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 2007;297:151-62. DOI PubMed
81. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with
metastatic melanoma. J Clin Oncol 2002;20:142-52. DOI
82. Chondrou P, Karapetsas A, Kiousi DE, et al. Lactobacillus paracasei K5 displays adhesion, anti-proliferative activity and apoptotic
effects in human colon cancer cells. Benef Microbes 2018;9:975-83. DOI
83. Leschner S, Westphal K, Dietrich N, et al. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong
hemorrhage promoted by TNF-alpha. PLoS One 2009;4:e6692. DOI PubMed PMC
84. Kasinskas RW, Forbes NS. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce
apoptosis. Cancer Res 2007;67:3201-9. DOI PubMed
85. Kwon SY, Thi-Thu Ngo H, Son J, Hong Y, Min JJ. Exploiting bacteria for cancer immunotherapy. Nat Rev Clin Oncol 2024;21:569-
89. DOI
86. Saito S, Cao DY, Maekawa T, Tsuji NM, Okuno A. Lactococcus lactis subsp. cremoris C60 upregulates macrophage function by
modifying metabolic preference in enhanced anti-tumor immunity. Cancers 2024;16:1928. DOI PubMed PMC
87. Herrero-Fresno A, Olsen JE. Salmonella Typhimurium metabolism affects virulence in the host - a mini-review. Food Microbiol
2018;71:98-110. DOI PubMed
88. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-
targeting in vivo. Nat Biotechnol 1999;17:37-41. DOI PubMed
89. Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically
modified strain of Salmonella typhimurium. J Infect Dis 2000;181:1996-2002. DOI PubMed
90. Song M, Kim HJ, Kim EY, et al. ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol
Chem 2004;279:34183-90. DOI
91. Na HS, Kim HJ, Lee HC, Hong Y, Rhee JH, Choy HE. Immune response induced by Salmonella typhimurium defective in ppGpp
synthesis. Vaccine 2006;24:2027-34. DOI PubMed
92. Sieow BF, Wun KS, Yong WP, Hwang IY, Chang MW. Tweak to treat: reprograming bacteria for cancer treatment. Trends Cancer
2021;7:447-64. DOI PubMed
93. Park SH, Zheng JH, Nguyen VH, et al. RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated
salmonella-mediated cancer therapy. Theranostics 2016;6:1672-82. DOI PubMed PMC
94. Massa PE, Paniccia A, Monegal A, de Marco A, Rescigno M. Salmonella engineered to express CD20-targeting antibodies and a
drug-converting enzyme can eradicate human lymphomas. Blood 2013;122:705-14. DOI
95. Wu D, Zhao Z, Liu H, et al. Escherichia coli Nissle 1917-driven microrobots for effective tumor targeted drug delivery and tumor
regression. Acta Biomater 2023;169:477-88. DOI
96. Zhu J, Ke Y, Liu Q, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer
immunotherapy. Nat Commun 2022;13:7466. DOI PubMed PMC
97. Zhou DX, Wang XH, Xu X, et al. Anti-tumor effects of engineered VNP20009-Abvec-Igκ-mPD-1 strain in melanoma mice via
combining the oncolytic therapy and immunotherapy. Pharmaceutics 2022;14:2789. DOI PubMed PMC
98. Ciaćma K, Więckiewicz J, Kędracka-Krok S, et al. Secretion of tumoricidal human tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) by recombinant Lactococcus lactis: optimization of in vitro synthesis conditions. Microb Cell Fact 2018;17:177.